The premise of the paradox: examining the evidence that motivated GIPR agonist and antagonist drug development programs
1. 系统已在2026-03-13 12:14:06对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
JD Douros, SA Mowery, PJ Knerr
Journal of Clinical Medicine, 2025
mdpi.com
… There is a GIPR small molecule antagonist (Pfizer, PF-07976016) in phase 2 clinical trials
(NCT06717425) but little information is currently available regarding its structure, in vitro profile…

